Table 2 Investigational agents in... | American Society of Hematology

Table 2

Investigational agents in relapsed FL

Agent	Classification	N	ORR, %	CR, %	Duration, 1-y PFS, %	Reference
Lenalidomide	Immunomodulator	45	53	20	55	69
Lenalidomide + rituximab	Immunomodulator	46	76	39	80	69
Duvelisib (IPI-145)	PI3K-δ and PI3K-γ inhibitor	13	69	38	80	70
Ibrutinib	BTK inhibitor	40	28	5	50	71
Venetoclax (ABT-199)	BCL-2 inhibitor	29	38	14	40	72
Polatuzumab vedotin + rituximab	Anti-CD79b antibody-drug conjugate	45	73	33	63	73
Obinutuzumab	Anti-CD20 monoclonal antibody	74	45	12	65	74

Agent	Classification	N	ORR, %	CR, %	Duration, 1-y PFS, %	Reference
Lenalidomide	Immunomodulator	45	53	20	55	69
Lenalidomide + rituximab	Immunomodulator	46	76	39	80	69
Duvelisib (IPI-145)	PI3K-δ and PI3K-γ inhibitor	13	69	38	80	70
Ibrutinib	BTK inhibitor	40	28	5	50	71
Venetoclax (ABT-199)	BCL-2 inhibitor	29	38	14	40	72
Polatuzumab vedotin + rituximab	Anti-CD79b antibody-drug conjugate	45	73	33	63	73
Obinutuzumab	Anti-CD20 monoclonal antibody	74	45	12	65	74